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Tissue Engineering of Vascular Bypass Grafts:
Role of Endothelial Cell Extraction
A. Tiwari, H. J. Salacinski, G. Hamilton and A. M. Seifalian∗
Vascular Haemodynamic Unit, University Department of Surgery, Royal Free and University College Medical School,
University College London and The Royal Free Hospital, London, U.K.
Surgical treatment of vascular disease has become common. The use of synthetic materials is limited to grafts larger than
5–6 mm, because of the frequency of occlusion observed with small-diameter prosthetics. An alternative would be a hybrid
or tissue-engineered graft with the surface coated with a monolayer of the patients’ own endothelial cells. This review
examines the various techniques and technologies used to date in order to extract endothelial cells for such graft
engineering.
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Introduction thetic materials most widely used as coronary and peri-
pheral bypass grafts in surgery and as A–V fistulae. To
Bypass surgery is a common treatment for coronary and date they have been particularly successful in ap-
peripheral vascular disease (PVD) which is the largest plications requiring large-diameter (>5 mm) vascular
cause of mortality in both the U.S.A. and Europe.1 Auto- substitutes in areas of high blood flow.6 However, in
genous vessels, particularly the saphenous vein of the low-flow or smaller diameter sites such as below-knee
leg, remain the standard for coronary grafting and peri- or coronary bypass, the grafts are compromised by both
pheral bypass surgery. However, up to 30% of patients thrombogenicity and compliance mismatch between
do not have veins suitable for vascular reconstruction the rigid graft and elastic host artery. This results in
duetovenous abnormality,poorqualityand lackofvein anastomotic intimal hyperplasia (IH), and finally sten-
due to previous surgery.2 In these patients prosthetic osis.7 Attempts have been made to decrease the surface
grafts are used, which to date have had comparatively thrombogencity of such grafts by incorporating endo-
high failure rates. This is principally due to a lack of an thelial cells extracted from numerous sources onto the
endothelial cell lining inside the graft and to compliance inner surface of prosthetic grafts.8–11
mismatch between rigid graft and elastic host artery. Initial attempts at tissue engineering a blood vessel
Consequently the development of a viable, compliant- substitute involved seeding the lumen of a synthetic
elasticity similar to arterial, small-diameter vascular by- graft with endothelial cells. Seeding involves extracting
pass graft(s) has been an area of intense focus.3,4 The autologous endothelial cells (EC) and then lining these
use of synthetic materials to fabricate a blood vessel cells onto the graft lumen. Herring,12,13 together with
substitute began over three decades ago and has led to Mansfield14 and co-workers, suggested that this would
vascular prostheses made from a variety of materials.5 provide a more biocompatible surface and thereby de-
Rigid expanded polytetrafluoroethylene (ePTFE) and crease thrombosis and IH. Herring and co-workers then
Dacron (polyethylene terephthalate fibre) are the syn- showed clinical evidence in humans that when a graft
was seeded, a lining of extensive endothelial cells was
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tissue engineering and involves the co-culture of cells techniques for cell extraction influences which tech-
nique might be used, with most institutions currentlywith natural and/or synthetic materials in order to cre-
ate a cellular vessel in vitro.18 Such vessels still require trying to develop a single-stage seeding procedure.
harvesting of the patients’ cells months in advance of
the required graft procedure as well as extensive culture
time, whereas a graft is often needed immediately and Sources of autologous cells
in a length of up to 1m, and to date bioreactor tech-
nology has extensive problems in generating tissues of Sources of autologous tissue are as follows: (a) veins;
this length. Moreover, the long-term in vivo efficacy of (b) arteries; (c) omental fat and (d) subcutaneous fat.
this approach has yet to be demonstrated in an extensive Pericardial fat has also been investigated as a source
clinical trial. The aim of this review is to critically ex- for use in coronary seeding, but only in animals.8 The
amine the technique/technologies used in retrieving general principles of extraction from these tissues have
these autologous cells as required for such hybrid de- involved two main strategies: (1) enzymatic loosening
vices. Indeed, no seeded or tissue-engineered vascular of endothelial cells from the tissue and (2) separation of
graft will ever achieve clinical acceptance until a re- cells from non-endothelial cells.
liable, quantifiable and easy to perform method is es- Typical enzymes used are crude collagenase, trypsin
tablished. or both. To date no one has tried utilising highly purified
sources with known, quantifiable and repeatable en-
zyme activities. Suggs and co-workers compared dif-
ferent batches of crude enzymes with partially/purified
sources and found harvesting efficiency between twoSearch
batches of crude collagenase enzymes from the same
manufacturer could differ by more than two- to three-Strategy methods
fold, and that by using a partially purified mixture a
more consistent harvest was obtained.9 Using purifiedAll the studies were identified by PubMed, ISIS and
CAS searches between years 1966–2000 with the fol- enzymes would reduce having to test each batch of the
enzyme for harvesting efficiency. Concentrations oflowing keywords: endothelial, mesothelial, seeding,
coronary, biomaterials and vascular prosthesis. trypsin used are variable, but using higher con-
centrations of trypsin and collagenase and longer
periods of incubation may lead to a better harvest, al-
though it may be detrimental to cell viability.20 Ranval
and co-workers showed that using papaverine, aOne-step versus two-step cell seeding of vascular grafts
smooth muscle relaxant, could also increase cell yield.21
This agent, however, is not commonly used.To understand the need for different sources and
procedures for EC extraction, it is important to under-
stand the two strategies being used to line autologous
cells. These are one-step and two-step seeding, often Results
called single- and two-stage seeding in the clinical lit-
erature.12,19 Single-stage involves extraction of EC and Endothelial cell extraction from large vessels: in vivo
then immediate use for seeding. Two-stage seeding is
where serial passaging is used to increase cellular num- The vessels used are the external and internal jugular
vein, the saphenous vein or occasionally the carotidbers prior to engineering of the graft. The cell culture
period can take 4–5 weeks.19 artery.12,14 Herring and co-workers used steel wool to
scrape the lumen of canine saphenous veins to im-A single-stage technique would be suitable for use
in patients suffering from claudication, rest pain and mediately seed the prosthetic graft. To this end, this was
the first reported single-stage seeding procedure.12 Ancritical ischaemia in limbsand acute coronary ischaemia
(unstable angina). Because of the time period required EC lining on the prosthetic graft was subsequently dem-
onstrated.22 It was calculated that an 800 mm segmentfor two-stage seeding, it is only suitable when an elect-
ive bypass procedure can be undertaken. Most bypass of vein would be needed to efficiently seed a standard
750 mm,ePTFE6 mmdiameterprostheticgraftandthussurgery is now undertaken for rest pain or critical isch-
aemia, so two-stage seeding is not appropriate. The this technique was abandoned.13 Currently two com-
mon techniques exist for extracting EC from blood ves-availability of the source of endothelial cells and the
experience of the medical institution to the different sels, these being cannulation and eversion.
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In cannulation, one end of the blood vessel is The techniques used in cell extraction are similar to
those used in animal studies, that is, cannulation andclamped, theotherendiscannulated, theenzymeadded
and the vessel clamped and incubated at 37 °C.23 In- eversion. Cannulation is the preferred technique in
humans. This would reflect the results as shown bycubation times are between 10 and 30 min. Prolonged
incubation leads to loosening of other non-endothelial Bourke and co-workers showing a higher cell yield with
the cannulation technique as indeed compared to ever-cells such as smooth muscle cells that affect cell culture
and the seeding procedure itself. At the end of the in- sion.24 With cannulation greater than 95%, cell viability
is expected in human trials.32cubation period, the enzyme and cell mixture is cent-
rifuged and the EC collected and used immediately in As with animal studies, the number of cells extracted
increases with the length of vein used. However, theseeding or left as a monolayer and cultured to increase
numbers, prior to usage later in a two-stage regimen. disadvantage with vein as a source of EC for seeding is
that only a limited number of cells can be extracted,Eversion involves everting the vessel over a stainless
steel rod, with the enzyme being added and incubated.10 ranging from 0.56×105 to 100×105 cells (see Table 1),
because of the short segments of vein available.32 TheseThe mixture is then collected and centrifuged as per
the cannulation technique. The results of cell extraction cells when seeded produce a low density on the graft
surface. This has no significant effect on patency, asusing eversion and cannulation along with the enzymes
used in these processes are summarised in Table 1, to- shown by the clinical trials of both Zilla and Herring
with their co-workers.33,34 Higher density seedinggether with detailed cellyield information. Most studies
have not calculated cell extraction based on the surface known as sodding was suggested which showed im-
proved clinical results.17 This requires cell culture, lim-area, so comparison of cell yield has been made by cal-
culating the surface area of the vein assuming a dia- iting this source only for a two-stage seeding
procedure.19meter of 6 mm as previously calculated by Bourke and
co-workers.24 When cells are cultured there is a 5–27% risk that cells
will not grow and that the mean number of days of cellThe cell yield increases with increasing length of vein.
Bourke and co-workers compared the cannulation tech- culture required to achieve enough cells to coat a PTFE
graft 700 mm long with 6 mm internal diameter isnique with the eversion technique in extracting EC from
the jugular vein of sheep and demonstrated a sig- 25±11 days.35 Smokers have significantly lower num-
bers of cell extracted and a longer culture time before thenificantly higher yield of cells with the cannulation tech-
nique.24 All of the above techniques used vein removed proliferation phase.36 This is significant, asmost patients
requiring bypass surgery are indeed smokers.36from an animal. Combe and co-workers demonstrated
that an in-situ technique of EC extraction from internal
jugular vein25 resulted in the vein re-endothelialising.
With this technique 36–74% of all EC could be extracted
Endothelial cell extraction from fat: general principlesand the vein could then be reused.
No direct comparison is available on cell yield using
Fat is an abundant source of EC, and is thereforethe two enzymes separately. Collagenase and trypsin
an ideal source for single-stage seeding. The cellsused together will give a cell yield using the eversion
extracted are known as microvascular endothelial cellstechnique ranging from 2×105 to 11.4×105 cells (see
(MVEC). The fat sources used in EC extraction areTable 1) in which 95% of the cells are viable as measured
omentum and subcutaneous fat. For coronary graftwith trypan blue exclusion assay with EC extracted
seeding, pericardial fat may also be a suitable source.from veins.26,27 Other uncommon techniques include
The fat is minced either with scalpel blades orchopping of the vessels before enzymatic/non-en-
mechanically in a blender. Mincing fat increases thezymatic degradation.14,28
surface area for enzymatic action and increases cell
yield. The enzymes used are collagenase or trypsin at
an equal or higher volume to the fat. The fat andEndothelial cell extraction from large vessels: clinical
studies enzyme mixture is then separated to extract pure EC.
Three techniques are available for separating the fat
The results of cell extraction from human veins and and enzyme mixture to extract EC. These are filtration,
centrifugation and percoll gradient.artery are summarised in Table 1. The veins used in
humans are the saphenous and external jugular veins.29, Filtration involves separation of the fat from the
mixture by passing it through a series of filters. These30 Forearm veins and arteries have also been used, but
not routinely.31 The saphenous vein is only used if it is filters of varying diameter allow adipocytes and red
blood cells to filter through, producing clumps ofunsuitable as a graft itself.
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Table 1. Endothelial cell extraction from vein.
Research workers Source Origin of cells Enzyme and Length/Surface Total cell Yield ×105/cm2
technique area of vein yield ×105
Graham et al., 198075,76 Canine Jugular C, T, E 120 mm (5.0–15.0) ∗∗0.69–2.10
Stanley et al., 198277 Canine Jugular C, T, E 100 mm 8.0 ∗∗1.30
Belden et al., 198211 Canine Jugular C, T, E 80 mm 2.0 ∗∗0.42
Schimdt et al., 198578 Canine Jugular C, T, E 80 mm 6.8 ∗∗1.40
Allen et al., 198427 Canine Jugular C, T, E 100 mm (50.0–100.0) ∗∗(4.20–8.30)
Kempczinski et al., 198579 Canine Jugular C, T, E 100–120 mm 7.5 ∗∗(1.0–1.3)
Rosenman et al., 198580 Canine Jugular C, T, E 120 mm 6.2 ∗∗0.86
Schmidt et al., 198420 Canine Jugular C, T, E 80 mm 6.0 1.30
Bourke et al., 198624 Sheep Jugular C, E NR NR 0.17
Bourke et al., 198624 Sheep Jugular C, CA NR NR 0.61
Hollier et al., 198681 Pig Jugular C, T, E 100 mm 2.5 ∗∗0.42
Pearce et al., 198726 Canine Jugular C, T, E 100 mm 1.5 ∗∗0.25
Douville et al., 198782 Canine Jugular C, T, E 100 mm 7.5 ∗∗1.30
Sterepetti et al., 198859 Canine Jugular C, E 120 mm (17.0–23.0) ∗∗2.40–3.20
Boyd et al., 198883 Canine Jugular C, T, E 100 mm 11.4 ∗∗1.9
Zilla et al., 199019 Baboon Jugular C, CA — — 0.12
Zilla et al., 199484 Baboon Jugular C, CA 45±8 mm 17.5±9.6 ∗∗6.50
Watkins et al., 198423 Human Saphenous vein C, CA 190±60 mm2 — 0.53±0.28
Zilla et al., 198733 Human ext. Jugular vein C, CA 490±166 mm2 — 0.53±0.28
Ortenwall et al., 198969 Human Saphenous vein C, CA 510±150 mm2 — 0.53±0.28
Zilla et al., 198985 Human Saphenous vein† C, CA — — 0.53±0.28
Zilla et al., 198986 Human Saphenous vein‡ C, CA — — 0.53±0.28
Ortenwall et al., 199071 Human Saphenous vein C, CA 590±150 mm2 — 0.53±0.28
Zilla et al., 199019 Human Saphenous vein C, CA — — 0.25±0.14
Kadletz et al., 199231 Human Forearm vein C, CA∗ 850–1050 mm2 — 0.53±0.28
Magometschnigg et al., 199288 Human Forearm vein C, CA 790±450 mm2 — 0.53±0.28
Jensen et al., 199432 Human Saphenous vein C, CA 80–150 mm 5.2 ∗∗0.57–1.08
Zilla et al., 199435,87 Human ext. Jugular vein C, CA 26±13 mm 0.56±0.03 0.19±0.13
Abbreviations: C; Collagenase, T; Trypsin, E; Eversion, CA; Cannulation, NR; Not Reported.
† Non-smoker, ‡ smoker, ∗ dispase enzyme, ∗∗ calculated.
Data either given as Mean±S.D. or as range (min–max).
Table 2. Endothelial cell extraction from omentum or subcutaneous fat.
Research workers Source Origin of cells Enzyme and technique Yield ×105/gm
Pearce et al., 198726 Canine Omentum C, CE 0.23
Sterpetti et al., 198859 Canine Omentum C, CE 10.0
Schmidt et al., 198858 Canine Omentum C, CE 30.0±8.0
Wang et al., 199038 Canine Omentum C, CE 13.0±2.0
Sterpetti et al., 199048 Canine Omentum C, CE 10.0
C, Percoll 4.0
Williams et al., 199260 Canine Omentum C, CE 11.0
Pasic et al., 199461 Canine Omentum C, CE, F 26.0±4.0
Sugimoto et al., 19898 Canine Pericardium C, CE 32.4±25.9
C, F 1.0±0.6
C, Percoll 0.6±0.5
Jarrel et al., 198639 Human cadavers Omentum C, Percoll 13.0±5.0
Anders et al., 198747 Human Omentum C, F 0.5
Rupnick et al., 198962 Human Omentum C, Percoll 12.0±5.0
Pronk et al., 199351 Human Omentum T, Ce 9.0/cm2
Sharp et al., 198930 Human Subcutaneous fat C, CE ∗6.8
Meerbaum et al., 199063 Human Liposuction fat C, F, CE 7.3
Human Subcutaneous fat C, F, CE 11.0
Vici et al., 199357 Human Subcutaneous fat C, Percoll (2.5–8.0)
Scott et al., 199589 Human Subcutaneous fat C, CE 0.22/cm2
William et al., 199972 Human Liposuction fat C, CE 10.0
Abbreviations: C; Collagenase, T; Trypsin, F; Filtration, CE; Centrifugation.
∗ Total yield. Data either given as Mean±S.D. or as range (min–max).
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Table 3. Summary of clinical trials of seeded grafts in humans.
Author EC source Type Graft Site of Seeding †Patency of grafts
of ID anastomosis density
graft (mm) ×105/cm2 Seeded Unseeded
Herring et al., 198770 External jugular vein PTFE 6 Fem n/k 93±7% at 3/12 84±10% at 3/12
82±12% at 12/12∗ 31±19% at 12/
12
Kadletz et al., 199231 Forearm vein PTFE 6 Fe 0.49±0.10 100% at 3/12
Meerbaum et al., 199063 Subcutaneous and ePTFE 6 Fem 42% at 30/12
liposuction fat Fe, femoro-
peroneal
Magometschnigg et al., Foreman vein ePTFE 6 Femorocrural 0.43±0.11 92% at 30 days 84±10% at 3/12
199288 31±19% at 12/
12
Fischlein et al., 199287 External jugular PTFE 6 Fem 80% at 30/12
Jensen et al., 199432 Saphenous vein Dacron — Aortofemoral 0.2 no difference
Zilla et al., 199435 External jugular PTFE 6 Fem 1.2 85% at 32/12∗ 55% at 32/12
Herring et al., 199434 External jugular PTFE — Fem — 38±9% at 30/12
Lesche et al., 199590 External jugular, PTFE 7 Fem 2.9±0.8 95±10% at 3/12
Saphenous vein 89±13% at 48/12
67±39% at 76/12
Williams 199972 Liposuction fat ePTFE — Ileoperoneal, Fe, 2.0 60±8% at 48/12 53% at 1/12
Iliotibial
Deutsch et al., 199917 External jugular/ ePTFE 6 Fem 65% at 108/12∗ 16% at 108/12
Cephalic
Laube et al., 200091 Vein ePTFE 4 Coronary artery 0.6 91% at 28/12
Abbreviations: Fem; Femoropopliteal, Fe; Femorotibial, ID; Internal Diameter.
† The patency presented in the table is a cumulative patency and has been calculated using the Kaplan–Meier life-table analysis. The
actual patency itself has been assessed by the research workers using duplex Doppler ultrasound and/or angiography in order to
determine the presence of flow in graft.
∗ p<0.04 comparison with control (unseeded).
endothelial cells which are stuck to the filter.37 The EC without staining by crystal violet or by trypan blue
which assess cell viability. In our experience we haveare then washed off and collected.
Centrifugation involves the mixture of fat and col- found immediate cell counting to be very difficult in
accurately quantifying cells, as the endothelial cellslagenase being centrifugated at 300–1000 g for
5–10 min.37,38 This separates the constituents into a top are difficult to differentiate from red blood cells and
the endothelial cells are usually clumped together.fat layer, a middle enzymatic layer and a bottom layer
of endothelial and red blood cells. The top and middle
layers are discarded and the bottom layer can then be
further washed and centifugated or used immediately
for seeding. This process does not give a pure layer Nature of endothelial cells extracted from fat
of EC, as cells are composed of a mixture of EC, red
blood cells and other cells such as fibroblasts. Controversy still exists surrounding the nature of the
cells extracted from omental fat. Some authors claimUsing percoll allows extraction of pure EC.39 The
process involves the pellet containing EC and blood that endothelial cells extracted from omental fat are
not endothelial cells but mesothelial cells.41–46 This hascells being suspended in percoll gradient and cent-
rifuged at high speeds of up to 20 000 g for period of been disputed by others.37,38,47–50 Both mesothelial cells
and endothelial cells can be characterised with the20 min. The percoll gradient separates the EC from
the rest of the cellular debris. commonly used EC markers, including von Willebrand
factor and CD34. However, when more extensiveMagnetic beads such as ulex coated Dynabeads have
also been used to extract pure EC.40 The Dynabeads markers are used only omental-derived cells stained
with cytokeratin 8 and 18 which is specific for meso-attach onto endothelial cells and are then removed
with a magnetic device. This technique has a poor thelial cells occur. Indeed, this is the basis for the later
disagreement.41,51,52uptake of endothelial cells, thus having to rely on cell
culturing, and as such is not suitable for single-stage The differentiation between mesothelial and endo-
thelial cells may only be academic as they both releaseseeding.
Once the cells have been extracted, a haemo- anticoagulant substances such as prostacyclin as well
as procoagulant substances.53–55 Cells derived fromcytometer is used for immediate cell counting with or
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subcutaneous fat are mainly endothelial, with only a with collagenase and dispase and when cultured
showed confluence of endothelial cell. The cells re-small percentage of mesothelial cells present.56,57
quired 2 weeks to reach confluence and this technique,
though causing minimal trauma to the patient, is
unsuitable for a single-stage seeding regimen.
Endothelial cell extraction from omentum: in vivo
experimental and clinical trials
The fat is incubated with the enzyme for 20–30 min.38,58
Clinical trials of seeded grafts in humansThe concentration of the enzymes used is variable but
can be up to 4 mg/ml.58 Canine sources have been Seeded grafts undergo endothelialisation in humans,commonly used in extracting EC from omentum and as first demonstrated in a graft removed 93 days afterthe results are summarised in Table 2.26,38,48,58–61 implantation.15 Initial trials of seeding measured theFor clinical trials, the limitation of using omentum effectiveness of the procedure measuring a thrombo-as a source of EC has been the need for a laparotomy gencity index, using isotope-labelled platelets to dem-with its consequent morbidity. However, with la- onstrate the effectiveness of seeding.67 Early results ofparoscopic surgery it may be possible to remove omen- seeding were mostly disappointing with some show-tum with minimal trauma to the patient. ing only moderate improvements in patency or throm-Initial attempts at extracting EC did not use just bogenicity index.33,67–71 This was thought to be due topure omentum, but a mixture of subcutaneous fat and the low density seeding, which shows no significantthe latter,37 or in the case of Jarrel39 also perinephric effect on patency.33 Seeded grafts also performed worsefat. The cell extraction technique and the cell yields if the patient was a smoker.68 When high densityare summarised in Table 2.39,47,51,62 seeding known as “sodding” was undertaken, patency
was improved.17 Clinical trials using subcutaneous fat
have shown inferior results as compared to two-stage
seeding using veins.17,72Endothelial cell extraction from subcutaneous fat: in vivo
The results of seeded and unseeded grafts whereexperimental and clinical trials
patency rates have been reported are summarised
in Table 3. The patency presented in the table is aThere is no need for a laparotomy when EC are
cumulative patency and has been calculated using theextracted from subcutaneous fat as they can be re-
Kaplan–Meier life-table analysis. The actual patencymoved by a small abdominal incision or by liposuction.
itself has been assessed by the research workers usingLiposuction has the advantage of a smaller incision
duplex Doppler ultrasound and/or angiography inand the fat extracted gives a better yield due to the
order to determine the presence of flow in graft.increased surface area which is available for enzymatic
digestion.63 With increasing experience, fat has been
extracted from the abdomen, thigh and buttock.63
Breast tissue has also been used for isolating endo-
thelial cells.40 The results of EC extraction from fat are Future Work
summarised in Table 2.
The commonly used techniques are centrifugation With the inferior results obtained for single-stage seed-
ing using microvascular endothelial cells, research isor percoll extraction.64 When percoll is used for cell
purification there is a poor expression for endothelial being undertaken to try and engineer the lumen with
artificial substances. Tissue-engineered biologicalcell markers by these cells and thus it is thought to be
a detrimental technique.57 Both percoll and filtration grafts hold the greatest promise, with the advantage
of low thrombogenicity and better long-term patencysignificantly reduce the number of endothelial cells
that can be extracted.8 There has been a consensus of than any currently available prosthetic graft.73,74
However, the length of culture time required toopinion recently that purifying microvascular cells
may have no beneficial effect and that a mixture of make them is restrictive, typically weeks to months,
and so makes them currently an unattractive pro-pure and mixed MVEC might equally be effective in
seeding vascular graft.65 position surgically. Further work is still required to
find an ideal vascular surface material onto whichKoyoama has recently described a technique for
extracting EC from subcutaneous fat by using a biopsy cells can be attached effectively, and work is underway
at our institution on such a revolutionary material.needle to extract 10 mg of fat.66 The fat was digested
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